



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Lilotomab

Cat. No.:	HY-P99707
CAS No.:	1453362-55-4
Target:	Apoptosis
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Lilotomab (HH1) is a murine anti-CD37 monoclonal antibody. Lilotomab reduces clonogenic survival. Lilotomab shows anti-tumor activity <sup>[1]</sup> .									
<b>IC<sub>50</sub> &amp; Target</b>	CD37 <sup>[1]</sup>									
<b>In Vitro</b>	<p>Lilotomab (0-40 µg/mL; 12 days) reduces the clonogenic survival of DOHH2 and Ramos cells<sup>[1]</sup>.            Lilotomab (40 µg/mL; 18 h) induces slight apoptosis in DOHH2 cells<sup>[1]</sup>.            MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Apoptosis Analysis<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>Ramos, DOHH2, Rec-1 cells</td> </tr> <tr> <td>Concentration:</td> <td>40 µg/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>18 h</td> </tr> <tr> <td>Result:</td> <td>Induced apoptosis in DOHH2 cells.</td> </tr> </table>		Cell Line:	Ramos, DOHH2, Rec-1 cells	Concentration:	40 µg/mL	Incubation Time:	18 h	Result:	Induced apoptosis in DOHH2 cells.
Cell Line:	Ramos, DOHH2, Rec-1 cells									
Concentration:	40 µg/mL									
Incubation Time:	18 h									
Result:	Induced apoptosis in DOHH2 cells.									
<b>In Vivo</b>	<p>Lilotomab (0.5 mg/kg; i.v.; once) inhibits tumor growth in mice<sup>[1]</sup>.            MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>SCID mice (DOHH2 cell xenografts)<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>0.5 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>I.v.; once</td> </tr> <tr> <td>Result:</td> <td>Inhibited tumor growth and increased mouse survival.</td> </tr> </table>		Animal Model:	SCID mice (DOHH2 cell xenografts) <sup>[1]</sup>	Dosage:	0.5 mg/kg	Administration:	I.v.; once	Result:	Inhibited tumor growth and increased mouse survival.
Animal Model:	SCID mice (DOHH2 cell xenografts) <sup>[1]</sup>									
Dosage:	0.5 mg/kg									
Administration:	I.v.; once									
Result:	Inhibited tumor growth and increased mouse survival.									

### REFERENCES

[1]. Malenge MM, et al. 177Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma. J Nucl Med. 2020

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA